Purpose: Cyclic hypoxia in tumors originates from heterogeneities in RBC flux and influences not only tumor cells but also endothelial cells lining tumor blood vessels. Whether pO 2 fluctuations, particularly transient reoxygenation periods, alter the well-known hypoxia-inducible factor (HIF)-dependent gene program is largely unknown.
Tumor hypoxia is nowadays recognized as a biologically unstable phenomenon (1) (2) (3) (4) (5) . This feature called intermittent or cyclic hypoxia may be described by considering two timescales of fluctuations (see ref. 6 for review). A lowfrequency wave (hours to days) is attributable to the remodeling of the angiogenic tumor vascular network (7, 8) , whereas shorter cycles (minutes to hours) are directly caused by variations in RBC flux within tumor microvessels (3, 9, 10) . Several mechanisms are described to account for these fluctuations including vasomotion of resistance vessels (11) (12) (13) and lack of deformability of hypoxic RBC (14, 15) . The phenotype of tumor cells is therefore directly influenced by the cyclic component of oxygen delivery in the tumor. Increased invasiveness and metastases were previously reported in response to tumor cell exposure to intermittent hypoxia (16, 17) . Another consequence, although poorly investigated, is that tumor microvessels, particularly endothelial cells at the interface with blood flow, are also influenced by fluctuations in O 2 -transporting RBC. This may occur directly through an unequal distribution of RBC at bifurcation points leading to a temporarily nonperfused vessel (or a vessel perfused with RBC-free serum; ref. 6 ). Cycles of angiogenesis/vascular remodeling may also favor conditions where a neovessel within a given tumor area may undergo fluctuations in pO 2 .
Here, we examined the effect of cyclic hypoxia on the transcriptomic profile of endothelial cells to get insights on pathways selectively triggered by fluctuations in pO 2 . The use of endothelial cells for this screening instead of tumor cells was justified because (a), as stated above, endothelial cells lining tumor blood vessels are also exposed to periods of hypoxia and this may therefore influence their phenotype, including their angiogenic potential, and (b) the use of genetically stable endothelial cells should allow to identify adaptation changes to cyclic hypoxia independently of alterations in the tumor cell genome (such as mutations or chromosome aberrations). We found that among a short list of differentially regulated genes by the O 2 status, prostaglandin synthase 2 (PTGS2) was a major target of cyclic hypoxia-triggered adaptation in endothelial cells and tumor cells. Using a pharmacologic inhibitor of cyclooxygenase-2 (COX-2; the protein encoded by PTGS2) and a dedicated COX-2 targeting small interfering RNA (siRNA) strategy, we identified the functional roles of this enzyme in driving endothelial cell survival and angiogenesis as well as the metastatic take of tumor cells preexposed to cyclic hypoxia.
Materials and Methods
Cell culture and hypoxia protocols. Human umbilical vein endothelial cells were routinely cultured in a specific endothelial cell growth medium (Lonza). Hepatocarcinoma cells (TLT) and cervix cancer cells (SiHa) were cultured in DMEM (Invitrogen) with 10% FCS. Before treatment, cells were serum starved; endothelial cells were incubated in endothelial basal medium (Lonza) and tumor cells were incubated in serum-free DMEM.
To reach and control hypoxic conditions, cells were transferred in a modular incubator chamber (BillupsRothenberg) and flushed for 10 min with a gas mixture of 5% CO 2 -95% N 2 gas until the chamber atmosphere reaches a pO 2 value of 0.5% (as determined by oximetry). The hypoxic chamber was then sealed and placed in a 37°C incubator for the selected period. The cyclic hypoxia protocol consisted of three periods of 1 h hypoxia interrupted by 30 min reoxygenation, whereas 3 h of uninterrupted exposure to hypoxia were used for the continuous hypoxia protocol. Cells were collected either at the end of hypoxia (the last period of hypoxia in the cycling protocol) or after increasing times of reoxygenation (Fig. 1A) . Cells maintained in normoxia were used as controls.
RNA isolation and microarray analysis. Total RNA was extracted with TriPure reagent (Roche). Quantification and integrity of RNA were assessed by the Agilent 2100 Bioanalyzer (Agilent Technologies). Microarray analysis was done on GeneChip Human Genome U133A 2.0 Array from Affymetrix. 1 Target labeling for the expression analysis was done from 5 μg total RNA and GeneChips were automatically stained and washed in a fluidics station as recommended by the manufacturer (Affymetrix). Genes were sorted as follows to determine the cyclic hypoxia signature: genes found to be "present" according to GeneChip operating software (Affymetrix) and their expression levels changed by a factor >2 (and maintained for at least 1 h) when comparing cyclic hypoxia versus normoxia and by a factor <2 when comparing continuous hypoxia versus normoxia as determined by Gene Spring software (Agilent Technologies).
Real-time quantitative PCR. Reverse transcription was done from total RNA using the SuperScript II RNase H − reverse transcriptase and random hexamer primers (Invitrogen). Real-time quantitative PCR (qPCR) analyses were done in triplicate using iQ SYBR Green Supermix (Bio-Rad). The following specific primers were designed according to GenBank sequence; HPRT (hypoxanthine phosphoribosyl transferase), ACTB (β-actin), and RPL19 (ribosomal protein L19) sets were used for the housekeeping genes.
Translational Relevance
This study identifies the PTGS2 gene as part of a transcriptomic signature induced by cyclic hypoxia and its protein product, cyclooxygenase-2 (COX-2), as a key mediator of both angiogenesis and metastases formation promoted by oxygen fluctuations. The induction of COX-2 in response to cyclic hypoxia is therefore associated with bad prognosis. This may be particularly relevant in the selection of cancer patients prone to receive COX inhibitors as adjunct treatments. Indeed, although the use of nonsteroidal anti-inflammatory drugs is associated with a better outcome for different cancer patients, reports of gastrointestinal toxicity and increased cardiovascular risk tend to limit the use of these drugs. Targeting COX inhibitors to the patient population selected based on a cyclic hypoxia gene signature could be a safer way to exploit the potential of these drugs. 
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PCR fluorescence data were obtained and analyzed with the IQ5 instrument (Bio-Rad). Ct (number of cycles needed to generate a fluorescent signal above a predefined threshold) was determined for each sample and the relative mRNA expression, expressed as fold variation, was calculated using the 2 −ΔΔCt formula after normalization to housekeeping genes (ΔCt) and determination of the difference in Ct (ΔΔCt) between the various conditions tested.
Immunoblotting. Cells were lysed in radioimmunoprecipitation assay buffer and immunoblotting was done on total cell extracts as described previously (18, 19) . Anti-COX-2 antibody was from Cayman Chemicals and anti-β-actin was from Sigma (Sigma-Aldrich).
Hypoxia-inducible factor-1α inhibition. To evaluate hypoxia-inducible factor (HIF) implication in COX-2 regulation, cells were incubated at the beginning of the hypoxia protocol with 10 ng/mL echinomycin, a HIF-1 DNA-binding activity inhibitor (Sigma), or its solvent DMSO. In other experiments, cells were transfected with HIF-1α targeting siRNA (AACTGGACACAGTGTGTTTGA) or with control, nontargeting siRNA (AllStars negative siRNA; Qiagen) using Lipofectin reagent (Invitrogen) 24 h before initiating the hypoxia protocols.
Prostaglandin production. Evaluation of COX-2 activity was made through immunoassay-based measurements of prostaglandins PgE 2 and PgF 1 a as PgI 2 stable metabolite Fig. 1 . Changes in mRNA expression in response to cyclic versus continuous hypoxia. A, protocols: endothelial and tumor cells were exposed to either three periods of 1 h hypoxia (0.5% O 2 ) interrupted by 30 min reoxygenation or three continuous hours of hypoxia, respectively. Cells were collected and lysed for further mRNA or protein extraction at the end of these protocols and at selected times after reoxygenation. Bar graphs show the relative gene expression (calculated from corresponding qPCR data) of (B) PTGS2, (C) ADAMTS1, and (D) BMP2 in endothelial cells at the indicated periods after cyclic (left) and continuous (right) hypoxia protocols. The reference value corresponds to the expression level in endothelial cells maintained in normoxic conditions (Nx). **, P < 0.005; ***, P < 0.001 versus normoxia (n = 3-9).
and TxB 2 as TxA 2 metabolite according to the manufacturer's instructions (Cayman Chemical). Prostaglandin release in the endothelial and tumor cell supernatants for a 18 h period (post-hypoxia) were determined and normalized in regard to the protein concentrations determined from the corresponding cell lysates.
Endothelial cell survival and tube formation assays. Cell survival was evaluated in a clonogenic assay according to a protocol previously developed (19) . This test (generally reserved to tumor cells) integrates a proapoptotic stress for endothelial cells that need to recover from a large dilution factor at the time of plating. Briefly, cells were seeded at 1,500 per 60 mm dish and submitted to hypoxia protocols 24 h later. Cells were then incubated for 7 days in full medium containing 10 μmol/L NS398 (COX-2 inhibitor) or DMSO (drug solvent) before crystal violet staining and counting of colonies. In some experiments, endothelial cells were transfected with a COX-2 targeting siRNA (AA-CACCGGAATTTTTGACAAG) or a negative control siRNA using Lipofectin reagent (Invitrogen) 24 h before initiating the hypoxia protocols.
Endothelial tube formation was determined in serumfree conditions by seeding 4 × 10 4 endothelial cells (preexposed or not to hypoxia protocols) in 24-well dishes containing Matrigel (BD Biosciences) and either exposed to 10 μmol/L NS398 (versus DMSO) or following COX-2 targeting siRNA transfection (versus negative control siRNA) or both. Formation of capillary-like tubular structures was assessed by counting the number of tube intersections in different fields and expressed as an angiogenic index.
Metastasis take and tumor cell survival. Metastasis take was determined by injecting 10 6 TLT tumor cells in the tail vein of NMRI mice. Tumor cells were either preexposed to intermittent hypoxia or maintained in normoxic conditions; cells were labeled with 5 μg/mL Cell Tracker Green CMFDA (Invitrogen). Mice were treated with NS398 (10 mg/kg) or vehicle (DMSO) through intraperitoneal administration 12 h before cell injections as well as at time 0 and 12 h post-injection. In some experiments, tumor cells were transfected with a COX-2 targeting siRNA (TAGGGAGTTCCTGACAAGAAA) or a negative control siRNA using Fugene reagent (Roche) 24 h before initiating the hypoxia protocols. In all the experiments, counting of viable cells was determined using a Nucleocounter apparatus (Chemometec) and the exact same number of viable cells was injected into mice. As an additional control (in parallel to the in vivo experiments of metastases formation), hypoxia-challenged and/or treated tumor cells were also seeded in 35 mm dishes and proliferation rates were determined after 24 h. Clonogenicity was also evaluated according to a protocol described previously (19) .
Mice were anesthetized 24 h after cell injection and blood was drained through perfusion of a physiologic solution in the right ventricle. Lungs were then collected, fixed overnight in 4% paraformaldehyde, and embedded in Tissue-Tek OCT (Sakura). Cryosections were observed with a fluorescence microscope to evaluate the number of extravasated tumor cells in the lung parenchyma.
Statistical analysis. Data are presented for convenience as mean ± SE. Statistical analyses were made using Student's t test or one-way ANOVA where appropriate.
Results
Cyclic hypoxia is associated with a specific gene expression profile in endothelial cells. To identify the actors that participate in the endothelial cell adaptation to cyclic hypoxia, we performed studies exploiting high-density microarray technology. We compared the transcriptomic patterns of endothelial cells exposed to cyclic hypoxia versus continuous hypoxia and normoxia (see schematic representation in Fig. 1A ). The protocol of cyclic hypoxia (1 h hypoxia/30 min reoxygenation) was based on previous measurements by our group of fluctuations in the tumor vasculature occurring at the frequency of 0.5 to 1 cycle per hour (5, 11, 20) .
We found that the expression of 231 genes was modified by a factor >2 in response to cyclic hypoxia versus normoxia. As stated in Materials and Methods, to be considered significantly altered, changes in gene expression had to be maintained for at least one more hour. Also, we further restricted this set of genes to those not similarly regulated by continuous hypoxia (the expression of which not modified by a factor >2 versus normoxic conditions). This led us to establish a short list of 12 genes upregulated by cyclic hypoxia (Table 1) .
Based on previously documented functions in endothelial cell biology, we picked three upregulated genes (ADAMTS1, BMP2, and PTGS2) and verified the extent of the changes in expression after cyclic hypoxia using qPCR. Slight differences were identified between microarray and qPCR data, but the preferential upregulation of ADAMTS1, BMP2, and PTGS2 in response to cyclic hypoxia was confirmed [3.0-, 2.3-, and 3.5-fold (P < 0.001; n = 3-9), respectively]. A time-course study, however, revealed that the upregulation of ADAMTS1, BMP2, and PTGS2 was very transient because the expression of each transcript was back to basal levels as soon as a few hours after the end of the last period of hypoxia (Fig. 1B-D, left) . No significant alteration in the expression of the three transcripts was observed in response to continuous hypoxia (Fig. 1B-D, right) .
Cyclic hypoxia induces COX-2 expression in a HIF-1α-dependent manner. Because of the previously reported role of COX-2 (the PTGS2 gene product) in preventing cell apoptosis in response to a large variety of stress, we then focused our work on this protein. Immunoblotting experiments revealed that the transient increase in COX-2 mRNA observed in response to cyclic hypoxia (see Fig. 1B ) did translate into an upregulation of COX-2 protein expression picking 6 to 18 h later ( Fig. 2A and B) . That continuous hypoxia did not affect on the COX-2 expression was also confirmed (Fig. 2C) . We reported previously that cyclic hypoxia stimulated the expression of HIF-1α despite the reoxygenation phases (19) . This finding was extended in this study where the extent of HIF-1α signal was found to be strikingly higher in response to cyclic 3 × 1 h hypoxia than continuous 3 h hypoxia (7.2-fold versus 2.1-fold; P < 0.01; n = 3; Fig. 2D ). To determine the role of HIF-1α in the upregulation of COX-2, we used echinomycin, a pharmacologic inhibitor of HRE binding as well as a specific siRNA targeting HIF-1α. Both echinomycin (Fig. 2E) and HIF-1α siRNA (Fig. 2F) prevented the increase in COX-2 mRNA transcript expression observed in response to cyclic hypoxia. Note that both strategies also reduced the expression of COX-2 mRNA in continuous hypoxia conditions ( Fig. 2E and F) .
Cyclic hypoxia stimulates endothelial cell survival and tubulogenesis in a COX-2-dependent manner. We then aimed to evaluate the role of COX-2 activity on endothelial cell survival and angiogenesis. Survival assays revealed that cyclic hypoxia significantly increased the number of endothelial cell colonies formed versus normoxia and continuous hypoxia (Fig. 3A) . We also used the COX-2 inhibitor NS398 (21) and a COX-2 targeting siRNA (75% silencing efficacy; P < 0.01; n = 3; see Supplementary Fig. S1A ) to determine the role of COX-2. Both strategies prevented cyclic hypoxia-dependent increase in endothelial cell survival, whereas they failed to significantly influence survival in cells exposed to normoxia or continuous hypoxia (Fig. 3A) . Similarly, whereas NS398 and a COX-2 targeting siRNA prevented the stimulatory effect of cyclic hypoxia on the capacity of endothelial cells to form tubes when cultured on Matrigel, they did not alter angiogenesis under normoxia (Fig. 3B) . Also, although continuous hypoxia slightly stimulated angiogenesis above background, this was not prevented by the presence of either NS398 or a COX-2 targeting siRNA (Fig. 3B) .
Cyclic hypoxia selectively increases COX-2 expression and activity in tumor cells. We then determined whether the increase in COX-2 expression in endothelial cells was a phenomenon also observed in tumor cells. Using both human and mouse tumor cell lines (cervix cancer SiHa and hepatocarcinoma TLT, respectively), we documented that COX-2 mRNA expression was upregulated in response to cyclic hypoxia (3 × 1 h) but not to 3 h continuous hypoxia (Fig. 4A) . As for endothelial cells, cyclic hypoxia-dependent increase in COX-2 mRNA was prevented by the use of the HIF-1α inhibitor echinomycin (Fig. 4B) . Importantly, the increase in COX-2 transcript in response to our short cyclic hypoxia protocol translated into an increase in COX-2 protein expression (Fig. 4C) and enzymatic activity as authenticated by the measurements of the production of PgE 2 , PgI 2 , and TxA 2 (Fig. 4D) . We found that cyclic hypoxia was associated with a strong production of either prostanoid, whereas continuous hypoxia did not influence COX-2 activity (Fig. 4C) . Of note, absolute levels of released prostaglandins were much higher in tumor cells than in endothelial cells (6.2 ± 1.4 versus 0.24 ± 0.02 ng PGE 2 /μg prostanoid, respectively; n = 6). A 50% higher level of PGE 2 production was, however, reproducibly observed in endothelial cells in response to cyclic hypoxia versus continuous hypoxia (data not shown).
Cyclic hypoxia stimulates metastasis formation in a COX-2-dependent manner. We finally determined the influence of cyclic hypoxia-driven COX-2 induction on the capacity of tumor cells to survive when injected in the bloodstream. The extent of metastatic tumor cells was determined by counting the number of extravasated tumor cells in the lungs 24 h after intravenous injection in mice. Tumor cells were preexposed to either cyclic or continuous hypoxia or maintained under normoxia and the exact same numbers of viable tumor cells (as determined by using an automated cell counter) were injected in mice. We found that cyclic hypoxia prechallenge significantly increased the number of tumor cells that could be detected in the lung parenchyma when compared with tumor cells preexposed to 3 h continuous hypoxia or normoxia (Fig. 5A and B) . To exclude a possible effect of hypoxia on long-term cell survival instead of tumor take per se, we also verified in parallel in vitro experiments that tumor cells did survive (Supplementary Fig. S2A ) and more importantly proliferate at the same rate whatever the preexposure to hypoxia (Fig. 5C) . Also, in vitro evaluation of long-term survival did not lead to significant differences in a clonogenic assay (Supplementary Fig. S2B ).
The effects of pharmacologic and genetic COX-2 inhibitory strategies were then evaluated by treating mice with NS398 or by pretransfecting tumor cells with a COX-2 targeting siRNA (Supplementary Fig. S1B ), respectively. Both Fig. 2 . Increase in COX-2 protein expression after cyclic hypoxia is HIF-1α dependent. Endothelial cells were cultured under normoxia or exposed to cyclic or continuous hypoxia as detailed in Fig. 1A . Cells were collected 6 h after the hypoxia protocols (A) or after the indicated periods (B and C). Cell lysates were then processed in Western blotting for COX-2 detection; the reference value corresponds to the COX-2 protein level in normoxic conditions. Cells were also collected directly at the end of either hypoxia protocols and immunoblotted for HIF-1α (D). In some experiments, endothelial cells were treated with 10 nmol/L echinomycin (E) or transfected with HIF-1α targeting siRNA (F); control cells were exposed to solvent (DMSO) or transfected with a negative control siRNA. Cells were then collected 1 h after the end of either hypoxia protocols and the effect of cyclic and continuous hypoxia versus normoxia on COX-2 mRNA expression was determined by qPCR analyses. *, P < 0.05; **, P < 0.005 versus corresponding untreated conditions (n = 3-4). treatments inhibited PgE 2 production ( Supplementary  Fig. S3A ) and, importantly, prevented cyclic hypoxiamediated increased metastases formation (Fig. 5D) . The lack of any deleterious effect of COX-2 inhibition on immediate cell survival and clonogenic potential was verified (see Supplementary Figs. S1C and S3B ). In addition, we took care to inject the exact same number of viable tumor cells in each condition and verified in parallel in vitro assays the absence of further discrepancies in cell proliferation rates (Fig. 5E) . Of note, when combining systemic NS398 treatment with COX-2 siRNA-transduced tumor cells, we did not observe any additional inhibitory effects on cyclic hypoxia-driven increase in metastases spreading, in agreement with NS398 acting through an inhibition of COX-2 activity (see Supplementary Fig. S4B ).
Discussion
Cyclic hypoxia is nowadays described as a more representative picture of the pO 2 environment in tumors than a permanent exposure to low O 2 levels (see Introduction). Here, we report that a specific transcriptomic signature is associated with cyclic hypoxia. This does not exclude genes known to be induced by continuous hypoxia but instead narrows the list of those hypoxia-regulated genes, the expression of which may resist, if not take advantage of, the reoxygenation periods. This study also provides new insights to regard endothelial cells lining tumor blood vessels as targets of hypoxia, although, at a first glance, the location of the endothelium at the interface with the blood tends to exclude vascular cells from the influence of low pO 2 .
To validate the functional effect of the preferential induction of some early genes in response to cyclic hypoxia (versus continuous hypoxia), we chose to focus on PTGS2, the COX-2 encoding gene. Indeed, whereas 3 h continuous hypoxia did not alter the expression of COX-2, three cycles of 1 h hypoxia/30 min reoxygenation led to a net induction of COX-2 mRNA and protein. Using both a specific COX-2 pharmacologic inhibitor and a dedicated COX-2 targeting siRNA, we showed that the endothelial cell survival and their capacity to form tubular structures, both promoted by cyclic hypoxia, were largely dependent on COX-2 activation. Our data further documented that whereas endogenous COX-2 activation in endothelial cells was sufficient to exert these proangiogenic effects (see Fig. 3A and B) , a similar COX-2 induction and the consecutive release of prostaglandins by tumor cells exposed to cyclic hypoxia (see Fig. 4 ) also supported a paracrine role of COX-2 activation in tumor cells. An increased metastatic potential was associated with the elevated COX-2 expression in tumor cells as proven by the use of pharmacologic and genetic COX-2 inhibitory strategies (see Fig. 5 ). Importantly, in our experimental metastases model, a cytotoxic effect of COX-2 inhibition could be excluded, thereby indicating that cyclic hypoxia-driven COX-2 activity accounted for an intrinsic increase in the metastatic capacity of (viable) tumor cells.
COX-2 was reported previously as a HIF-1α target in tumor cells (22) and endothelial cells (23) . Our data identify the PTGS2/COX-2 gene as a critical target of HIF-1α in response to cyclic hypoxia. The higher extent of HIF-1α stabilization in response to cyclic hypoxia (versus continuous hypoxia; Fig. 2D ) certainly accounts for the observed striking increase in COX-2 expression. This process may be further reinforced by the recently reported positive feedback loop wherein the induction of COX-2, through the production of PgE 2 , promotes HIF-1 transcriptional activity and Fig. 3 . Cyclic hypoxia induces endothelial cell proliferation and tube formation in a COX-2-dependent manner. Endothelial cells were cultured under normoxia or exposed to cyclic or continuous hypoxia as detailed in Fig. 1A . In some experiments, cells were treated with the COX-2 inhibitor NS398 (10 μmol/L) or a COX-2 targeting siRNA. Control cells were either exposed to solvent (DMSO) or transfected with a control siRNA (data from these two controls were pooled in bar graphs). A, extent of endothelial cell survival determined in a clonogenic assay by counting the number of colonies of >50 cells; data are expressed as fold change versus control conditions in normoxia. B, angiogenic index determined by measuring the number of tube intersections formed 12 h after plating on Matrigel. Inset, representative picture of computerized tube network formed in control conditions (left) or in the presence of NS398 (middle) or COX-2 targeting siRNA (right) under cyclic hypoxia. *, P < 0.05; **, P < 0.005 versus corresponding normoxic condition; §, P < 0.05; § §, P < 0.005 versus untreated cyclic hypoxia condition (n = 3-6). vascular endothelial growth factor induction (22) . Thus, although, paradoxically, the reoxygenation or lesser hypoxia phases (which alternate in tumors with periods of deep hypoxia) were anticipated to abrogate the induction of HRE-containing genes, our data indicate that a HIF responder gene such as PTGS2 remains upregulated in response to cyclic hypoxia and actually to a larger extent than in response to continuous hypoxia. Interestingly, it should be noted that both pharmacologic and genetic blockades of HIF-1α failed to completely prevent the effect of cyclic hypoxia on PTGS2 expression (Fig. 2E and  F) . This suggests the possible synergistic effects of other transcription factors triggered by the alternation of hypoxia-reoxygenation. In particular, ROS-dependent activation of sensitive transcription factors is currently examined in our laboratory using ADAMTS1 and BMP2 as a model because, contrary to PTGS2, we could not block their induction by cyclic hypoxia through HIF-1α inhibition (data not shown).
The status of COX-2 as a marker of cancer progression is matter of debate: both positive and negative correlations are reported in the literature (24) (25) (26) (27) (28) (29) (30) . Although this may arise from methodologic aspects such as multivariable versus univariable analysis or the mode of scoring, the multiple regulatory pathways leading to PTGS2 upregulation could also account for part of these discrepancies (the nature of coregulated genes could then help to determine whether PTGS2 expression is associated with poor patient survival). Our data indicate that, in the context of intermittent hypoxia, COX-2 is associated with not only angiogenesis but also metastases and could therefore be part of a signature associated with bad prognosis.
Interestingly, PTGS2/COX-2 was recently identified as a key actor in metastatic progression in preclinical and clinical studies (31) . Using the same set of patients, we found that 81% of the genes associated with PTGS2/COX-2 upregulation in our experiments could discriminate between patients with or without metastases ( Supplementary Fig. S5 ). Interestingly, the same authors recently reported that the COX-2 expression actively participated in the assembly of new tumor blood vessels and favored the breaching of capillaries leading to the intravasation of tumor cells and their seeding as distant metastases (32) , the latter process being blocked by mouse pretreatment with celecoxib, a COX inhibitor. Together with our data documenting the higher NS398-sensitive metastatic potential of cells submitted to cyclic hypoxia (Fig. 5) , these data give credential to a role of acute modulations of the local tumor pO 2 in tumor cell invasiveness. Importantly, our results using a pharmacologic COX-2 inhibitor were confirmed by using a dedicated COX-2 targeting siRNA, excluding in our experiments a potential COX-2-independent effect of the NS398 compound, as reported previously (33) . Also, when combining pharmacologic COX-2 inhibition with NS398 and COX-2 siRNA-transfected endothelial or tumor cells, we did not observe any additional inhibitory effects on cyclic hypoxia-promoted angiogenesis and metastases, in agreement with NS398 acting through an inhibition of COX-2 activity (see Supplementary Fig. S4A and B).
In conclusion, our study identified the PTGS2 gene as part of a transcriptomic signature induced by cyclic hypoxia and its protein product, COX-2, as a key mediator of angiogenesis and formation of metastases both promoted by O 2 fluctuations. Together with the observation that cyclic hypoxia favors COX-2 expression and activity also in tumor cells, these findings provide a new rationale to select cancer patients who may benefit from COX inhibitors. 5 . Cyclic hypoxia stimulates the take of intravenously injected tumor cells in the lung in a COX-2-dependent manner. Tumor cells exposed to cyclic or continuous hypoxia (as detailed in Fig. 1A ) versus normoxia were injected in mice treated with NS398 or vehicle (DMSO) or maintained in culture to evaluate proliferation rates. In some experiments, tumor cells were first transfected with a COX-2 targeting siRNA or a negative control siRNA; data from the two controls were pooled in bar graphs. Cells were prestained in vitro with a fluorescent cell tracker before injection. A, representative pictures of tumor cells detected from lung cryosections. Bar graphs represent the number of tumor cells detected per microscopic field (B) according to the cyclic or continuous hypoxia protocols and (D) after NS398 treatment or COX-2 siRNA transfection of cells exposed to cyclic hypoxia. C and E, in vitro proliferation rate of tumor cells treated as in B and D, respectively. *, P < 0.05; **, P < 0.005; ***, P < 0.001 versus cyclic hypoxia condition (n = 7-12).
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